Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 3:03 AM
Ignite Modification Date: 2025-12-25 @ 3:03 AM
NCT ID: NCT03158233
Eligibility Criteria: Inclusion Criteria: 1. Aged 15 to 40 years on the day of inclusion, currently residing in the site zone, and planning to continue to reside in the site zone for the duration of the study 2. For subjects under the age of majority on the day of inclusion: the assent form has been signed and dated by the subject (if required by local regulations), and the informed consent form has been signed and dated by the parent(s) or legal guardian(s). For subjects at or over the age of majority on the day of inclusion: the informed consent form has been signed and dated. 3\) Subject (and parent/guardian if subject is under the age of majority) able to attend all scheduled visits and to comply with all study procedures 4) In good health, based on medical history and physical examination Exclusion Criteria: 1. Subject is pregnant (as self-reported) 2. Participation in the 4 weeks preceding enrollment, or planned participation during the present study period, in a clinical trial investigating a vaccine, drug, medical device, or a medical procedure 3. Receipt of any dengue or yellow fever vaccine in the 4 weeks preceding the day of enrollment or planned receipt of any dengue or yellow fever vaccine during the study period 4. Receipt of immune globulins, blood or blood-derived products in the past 3 months 5. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) 6. History of Zika virus disease, confirmed either clinically, serologically, or virologically 7. Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion 8. Current alcohol abuse or drug addiction 9. Deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized involuntarily 10. Identified as an investigator or an employee of the investigator or study center, with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 15 Years
Maximum Age: 40 Years
Study: NCT03158233
Study Brief:
Protocol Section: NCT03158233